Eintrag weiter verarbeiten
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial
Gespeichert in:
| Zeitschriftentitel: | Journal of the American Heart Association |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , |
| In: | Journal of the American Heart Association, 7, 2018, 15 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Dagenais, Gilles R. Jung, Hyejung Lonn, Eva Bogaty, Peter M. Dehghan, Mahshid Held, Claes Avezum, Alvaro Jansky, Petr Keltai, Matyàs Leiter, Lawrence A. Lopez‐Jaramillo, Patricio Toff, William D. Bosch, Jackie Yusuf, Salim Dagenais, Gilles R. Jung, Hyejung Lonn, Eva Bogaty, Peter M. Dehghan, Mahshid Held, Claes Avezum, Alvaro Jansky, Petr Keltai, Matyàs Leiter, Lawrence A. Lopez‐Jaramillo, Patricio Toff, William D. Bosch, Jackie Yusuf, Salim |
|---|---|
| author |
Dagenais, Gilles R. Jung, Hyejung Lonn, Eva Bogaty, Peter M. Dehghan, Mahshid Held, Claes Avezum, Alvaro Jansky, Petr Keltai, Matyàs Leiter, Lawrence A. Lopez‐Jaramillo, Patricio Toff, William D. Bosch, Jackie Yusuf, Salim |
| spellingShingle |
Dagenais, Gilles R. Jung, Hyejung Lonn, Eva Bogaty, Peter M. Dehghan, Mahshid Held, Claes Avezum, Alvaro Jansky, Petr Keltai, Matyàs Leiter, Lawrence A. Lopez‐Jaramillo, Patricio Toff, William D. Bosch, Jackie Yusuf, Salim Journal of the American Heart Association Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial Cardiology and Cardiovascular Medicine |
| author_sort |
dagenais, gilles r. |
| spelling |
Dagenais, Gilles R. Jung, Hyejung Lonn, Eva Bogaty, Peter M. Dehghan, Mahshid Held, Claes Avezum, Alvaro Jansky, Petr Keltai, Matyàs Leiter, Lawrence A. Lopez‐Jaramillo, Patricio Toff, William D. Bosch, Jackie Yusuf, Salim 2047-9980 Ovid Technologies (Wolters Kluwer Health) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1161/jaha.118.008918 <jats:sec xml:lang="en"> <jats:title>Background</jats:title> <jats:p xml:lang="en">It is not clear whether the effects of lipid‐lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE‐3 (Heart Outcomes Prevention Evaluation) trial.</jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Methods and Results</jats:title> <jats:p xml:lang="en"> In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease ( <jats:styled-content style="fixed-case">CVD</jats:styled-content> ) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow‐up was 5.6 years. The outcome was a composite of <jats:styled-content style="fixed-case">CVD</jats:styled-content> events. Adjusted hazard ratios ( <jats:styled-content style="fixed-case">HRs</jats:styled-content> ) and 95% confidence intervals ( <jats:styled-content style="fixed-case">CIs</jats:styled-content> ) were estimated using Cox regression models. Participants with ≥2 healthy lifestyle factors had a lower rate of <jats:styled-content style="fixed-case">CVD</jats:styled-content> compared with those with fewer factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.85; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.73–1.00). Rosuvastatin reduced <jats:styled-content style="fixed-case">CVD</jats:styled-content> events in participants with ≥2 healthy lifestyle factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.74; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.62–0.90) and in participants with <2 factors ( <jats:styled-content style="fixed-case">HR</jats:styled-content> : 0.79; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.61–1.01). Consistent results were observed with combination therapy (≥2 factors: <jats:styled-content style="fixed-case">HR</jats:styled-content> : 0.74; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.57–0.97; <2 factors: <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.61; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.43–0.88). Candesartan/hydrochlorothiazide tends to reduce <jats:styled-content style="fixed-case">CVD</jats:styled-content> only in participants with <2 healthy lifestyle factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.78; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.61–1.00). </jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Conclusions</jats:title> <jats:p xml:lang="en"> Healthy lifestyles are associated with lower <jats:styled-content style="fixed-case">CVD</jats:styled-content> . Rosuvastatin alone and combined with candesartan/hydrochlorothiazide is beneficial regardless of healthy lifestyle status; however, the benefit of antihypertensive treatment appears to be limited to patients with less healthy lifestyles. </jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Clinical Trial Registration</jats:title> <jats:p xml:lang="en"> <jats:styled-content style="fixed-case">URL</jats:styled-content> : <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link> . Unique identifier: <jats:styled-content style="fixed-case">NCT</jats:styled-content> 00239681. </jats:p> </jats:sec> Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial Journal of the American Heart Association |
| doi_str_mv |
10.1161/jaha.118.008918 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9qYWhhLjExOC4wMDg5MTg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9qYWhhLjExOC4wMDg5MTg |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2018 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2018 |
| issn |
2047-9980 |
| issn_str_mv |
2047-9980 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
dagenais2018effectsoflipidloweringandantihypertensivetreatmentsinadditiontohealthylifestylesinprimarypreventionananalysisofthehope3trial |
| publishDateSort |
2018 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of the American Heart Association |
| source_id |
49 |
| title |
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_unstemmed |
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_full |
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_fullStr |
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_full_unstemmed |
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_short |
Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_sort |
effects of lipid‐lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention: an analysis of the hope‐3 trial |
| topic |
Cardiology and Cardiovascular Medicine |
| url |
http://dx.doi.org/10.1161/jaha.118.008918 |
| publishDate |
2018 |
| physical |
|
| description |
<jats:sec xml:lang="en">
<jats:title>Background</jats:title>
<jats:p xml:lang="en">It is not clear whether the effects of lipid‐lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE‐3 (Heart Outcomes Prevention Evaluation) trial.</jats:p>
</jats:sec>
<jats:sec xml:lang="en">
<jats:title>Methods and Results</jats:title>
<jats:p xml:lang="en">
In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease (
<jats:styled-content style="fixed-case">CVD</jats:styled-content>
) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow‐up was 5.6 years. The outcome was a composite of
<jats:styled-content style="fixed-case">CVD</jats:styled-content>
events. Adjusted hazard ratios (
<jats:styled-content style="fixed-case">HRs</jats:styled-content>
) and 95% confidence intervals (
<jats:styled-content style="fixed-case">CIs</jats:styled-content>
) were estimated using Cox regression models. Participants with ≥2 healthy lifestyle factors had a lower rate of
<jats:styled-content style="fixed-case">CVD</jats:styled-content>
compared with those with fewer factors (
<jats:styled-content style="fixed-case">HR:</jats:styled-content>
0.85; 95%
<jats:styled-content style="fixed-case">CI</jats:styled-content>
, 0.73–1.00). Rosuvastatin reduced
<jats:styled-content style="fixed-case">CVD</jats:styled-content>
events in participants with ≥2 healthy lifestyle factors (
<jats:styled-content style="fixed-case">HR:</jats:styled-content>
0.74; 95%
<jats:styled-content style="fixed-case">CI</jats:styled-content>
, 0.62–0.90) and in participants with <2 factors (
<jats:styled-content style="fixed-case">HR</jats:styled-content>
: 0.79; 95%
<jats:styled-content style="fixed-case">CI</jats:styled-content>
, 0.61–1.01). Consistent results were observed with combination therapy (≥2 factors:
<jats:styled-content style="fixed-case">HR</jats:styled-content>
: 0.74; 95%
<jats:styled-content style="fixed-case">CI</jats:styled-content>
, 0.57–0.97; <2 factors:
<jats:styled-content style="fixed-case">HR:</jats:styled-content>
0.61; 95%
<jats:styled-content style="fixed-case">CI</jats:styled-content>
, 0.43–0.88). Candesartan/hydrochlorothiazide tends to reduce
<jats:styled-content style="fixed-case">CVD</jats:styled-content>
only in participants with <2 healthy lifestyle factors (
<jats:styled-content style="fixed-case">HR:</jats:styled-content>
0.78; 95%
<jats:styled-content style="fixed-case">CI</jats:styled-content>
, 0.61–1.00).
</jats:p>
</jats:sec>
<jats:sec xml:lang="en">
<jats:title>Conclusions</jats:title>
<jats:p xml:lang="en">
Healthy lifestyles are associated with lower
<jats:styled-content style="fixed-case">CVD</jats:styled-content>
. Rosuvastatin alone and combined with candesartan/hydrochlorothiazide is beneficial regardless of healthy lifestyle status; however, the benefit of antihypertensive treatment appears to be limited to patients with less healthy lifestyles.
</jats:p>
</jats:sec>
<jats:sec xml:lang="en">
<jats:title>Clinical Trial Registration</jats:title>
<jats:p xml:lang="en">
<jats:styled-content style="fixed-case">URL</jats:styled-content>
:
<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link>
. Unique identifier:
<jats:styled-content style="fixed-case">NCT</jats:styled-content>
00239681.
</jats:p>
</jats:sec> |
| container_issue |
15 |
| container_start_page |
0 |
| container_title |
Journal of the American Heart Association |
| container_volume |
7 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792323813881413633 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:39:47.942Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Effects+of+Lipid%E2%80%90Lowering+and+Antihypertensive+Treatments+in+Addition+to+Healthy+Lifestyles+in+Primary+Prevention%3A+An+Analysis+of+the+HOPE%E2%80%903+Trial&rft.date=2018-08-07&genre=article&issn=2047-9980&volume=7&issue=15&jtitle=Journal+of+the+American+Heart+Association&atitle=Effects+of+Lipid%E2%80%90Lowering+and+Antihypertensive+Treatments+in+Addition+to+Healthy+Lifestyles+in+Primary+Prevention%3A+An+Analysis+of+the+HOPE%E2%80%903+Trial&aulast=Yusuf&aufirst=Salim&rft_id=info%3Adoi%2F10.1161%2Fjaha.118.008918&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792323813881413633 |
| author | Dagenais, Gilles R., Jung, Hyejung, Lonn, Eva, Bogaty, Peter M., Dehghan, Mahshid, Held, Claes, Avezum, Alvaro, Jansky, Petr, Keltai, Matyàs, Leiter, Lawrence A., Lopez‐Jaramillo, Patricio, Toff, William D., Bosch, Jackie, Yusuf, Salim |
| author_facet | Dagenais, Gilles R., Jung, Hyejung, Lonn, Eva, Bogaty, Peter M., Dehghan, Mahshid, Held, Claes, Avezum, Alvaro, Jansky, Petr, Keltai, Matyàs, Leiter, Lawrence A., Lopez‐Jaramillo, Patricio, Toff, William D., Bosch, Jackie, Yusuf, Salim, Dagenais, Gilles R., Jung, Hyejung, Lonn, Eva, Bogaty, Peter M., Dehghan, Mahshid, Held, Claes, Avezum, Alvaro, Jansky, Petr, Keltai, Matyàs, Leiter, Lawrence A., Lopez‐Jaramillo, Patricio, Toff, William D., Bosch, Jackie, Yusuf, Salim |
| author_sort | dagenais, gilles r. |
| container_issue | 15 |
| container_start_page | 0 |
| container_title | Journal of the American Heart Association |
| container_volume | 7 |
| description | <jats:sec xml:lang="en"> <jats:title>Background</jats:title> <jats:p xml:lang="en">It is not clear whether the effects of lipid‐lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE‐3 (Heart Outcomes Prevention Evaluation) trial.</jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Methods and Results</jats:title> <jats:p xml:lang="en"> In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease ( <jats:styled-content style="fixed-case">CVD</jats:styled-content> ) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow‐up was 5.6 years. The outcome was a composite of <jats:styled-content style="fixed-case">CVD</jats:styled-content> events. Adjusted hazard ratios ( <jats:styled-content style="fixed-case">HRs</jats:styled-content> ) and 95% confidence intervals ( <jats:styled-content style="fixed-case">CIs</jats:styled-content> ) were estimated using Cox regression models. Participants with ≥2 healthy lifestyle factors had a lower rate of <jats:styled-content style="fixed-case">CVD</jats:styled-content> compared with those with fewer factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.85; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.73–1.00). Rosuvastatin reduced <jats:styled-content style="fixed-case">CVD</jats:styled-content> events in participants with ≥2 healthy lifestyle factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.74; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.62–0.90) and in participants with <2 factors ( <jats:styled-content style="fixed-case">HR</jats:styled-content> : 0.79; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.61–1.01). Consistent results were observed with combination therapy (≥2 factors: <jats:styled-content style="fixed-case">HR</jats:styled-content> : 0.74; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.57–0.97; <2 factors: <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.61; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.43–0.88). Candesartan/hydrochlorothiazide tends to reduce <jats:styled-content style="fixed-case">CVD</jats:styled-content> only in participants with <2 healthy lifestyle factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.78; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.61–1.00). </jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Conclusions</jats:title> <jats:p xml:lang="en"> Healthy lifestyles are associated with lower <jats:styled-content style="fixed-case">CVD</jats:styled-content> . Rosuvastatin alone and combined with candesartan/hydrochlorothiazide is beneficial regardless of healthy lifestyle status; however, the benefit of antihypertensive treatment appears to be limited to patients with less healthy lifestyles. </jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Clinical Trial Registration</jats:title> <jats:p xml:lang="en"> <jats:styled-content style="fixed-case">URL</jats:styled-content> : <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link> . Unique identifier: <jats:styled-content style="fixed-case">NCT</jats:styled-content> 00239681. </jats:p> </jats:sec> |
| doi_str_mv | 10.1161/jaha.118.008918 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9qYWhhLjExOC4wMDg5MTg |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2018 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2018 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 2047-9980 |
| issn_str_mv | 2047-9980 |
| language | English |
| last_indexed | 2024-03-01T11:39:47.942Z |
| match_str | dagenais2018effectsoflipidloweringandantihypertensivetreatmentsinadditiontohealthylifestylesinprimarypreventionananalysisofthehope3trial |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Journal of the American Heart Association |
| source_id | 49 |
| spelling | Dagenais, Gilles R. Jung, Hyejung Lonn, Eva Bogaty, Peter M. Dehghan, Mahshid Held, Claes Avezum, Alvaro Jansky, Petr Keltai, Matyàs Leiter, Lawrence A. Lopez‐Jaramillo, Patricio Toff, William D. Bosch, Jackie Yusuf, Salim 2047-9980 Ovid Technologies (Wolters Kluwer Health) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1161/jaha.118.008918 <jats:sec xml:lang="en"> <jats:title>Background</jats:title> <jats:p xml:lang="en">It is not clear whether the effects of lipid‐lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE‐3 (Heart Outcomes Prevention Evaluation) trial.</jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Methods and Results</jats:title> <jats:p xml:lang="en"> In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease ( <jats:styled-content style="fixed-case">CVD</jats:styled-content> ) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow‐up was 5.6 years. The outcome was a composite of <jats:styled-content style="fixed-case">CVD</jats:styled-content> events. Adjusted hazard ratios ( <jats:styled-content style="fixed-case">HRs</jats:styled-content> ) and 95% confidence intervals ( <jats:styled-content style="fixed-case">CIs</jats:styled-content> ) were estimated using Cox regression models. Participants with ≥2 healthy lifestyle factors had a lower rate of <jats:styled-content style="fixed-case">CVD</jats:styled-content> compared with those with fewer factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.85; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.73–1.00). Rosuvastatin reduced <jats:styled-content style="fixed-case">CVD</jats:styled-content> events in participants with ≥2 healthy lifestyle factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.74; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.62–0.90) and in participants with <2 factors ( <jats:styled-content style="fixed-case">HR</jats:styled-content> : 0.79; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.61–1.01). Consistent results were observed with combination therapy (≥2 factors: <jats:styled-content style="fixed-case">HR</jats:styled-content> : 0.74; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.57–0.97; <2 factors: <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.61; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.43–0.88). Candesartan/hydrochlorothiazide tends to reduce <jats:styled-content style="fixed-case">CVD</jats:styled-content> only in participants with <2 healthy lifestyle factors ( <jats:styled-content style="fixed-case">HR:</jats:styled-content> 0.78; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> , 0.61–1.00). </jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Conclusions</jats:title> <jats:p xml:lang="en"> Healthy lifestyles are associated with lower <jats:styled-content style="fixed-case">CVD</jats:styled-content> . Rosuvastatin alone and combined with candesartan/hydrochlorothiazide is beneficial regardless of healthy lifestyle status; however, the benefit of antihypertensive treatment appears to be limited to patients with less healthy lifestyles. </jats:p> </jats:sec> <jats:sec xml:lang="en"> <jats:title>Clinical Trial Registration</jats:title> <jats:p xml:lang="en"> <jats:styled-content style="fixed-case">URL</jats:styled-content> : <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link> . Unique identifier: <jats:styled-content style="fixed-case">NCT</jats:styled-content> 00239681. </jats:p> </jats:sec> Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial Journal of the American Heart Association |
| spellingShingle | Dagenais, Gilles R., Jung, Hyejung, Lonn, Eva, Bogaty, Peter M., Dehghan, Mahshid, Held, Claes, Avezum, Alvaro, Jansky, Petr, Keltai, Matyàs, Leiter, Lawrence A., Lopez‐Jaramillo, Patricio, Toff, William D., Bosch, Jackie, Yusuf, Salim, Journal of the American Heart Association, Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial, Cardiology and Cardiovascular Medicine |
| title | Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_full | Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_fullStr | Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_full_unstemmed | Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_short | Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| title_sort | effects of lipid‐lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention: an analysis of the hope‐3 trial |
| title_unstemmed | Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial |
| topic | Cardiology and Cardiovascular Medicine |
| url | http://dx.doi.org/10.1161/jaha.118.008918 |